Skip to main content
SpringerLink
Log in

Epidemiologic Benefits of Pneumococcal Vaccine Introduction into Preventive Vaccination Programs

  • Chapter
  • First Online:
Medical Research and Innovation

Part of the book series: Advances in Experimental Medicine and Biology ((CLEXBI,volume 1324))

Abstract

Vaccination against pneumococci is one of the most effective methods of preventing pneumococcal diseases. Currently, 10- and 13-valent conjugate vaccines (PCV10 and PCV13) and 23-valent polysaccharide vaccine (PPSV23) are used. Only the conjugate vaccines are used in children. The PCV can be used both in children and adults, but children can receive only PCV. A side effect of vaccination was that bacterial serotypes not included in a vaccine started increasingly emerging in pneumococcal infections, replacing the serotypes eliminated by the vaccine. The basic vaccination schedule consists of three or four doses, according to the country’s recommendation. In Poland, it consists of two primary doses followed by a supplementary dose of the PCV-10, with some modifications in case of specific risk factors. The use of preventive vaccinations has helped reduce antibiotic resistance, as serotypes characterized by a rapid acquisition of drug resistance are included in the vaccine serologic spectrum, making their environment prevalence decrease. The research is currently underway on conjugate vaccines that contain a greater number of bacterial serotypes and on more universal vaccines that would eliminate the emergence of new serotypes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ahman H, Kayhty H, Lehtonen H, Leroy O, Froeschle J, Eskola J (1998) Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 17(3):211–216

    Article  CAS  Google Scholar 

  • Australian Government (2020) Department of Health: National immunization program schedule for all non-indigenous people. https://www.health.gov.au/resources/publications/national-immunization-program-schedule-for-all-non-indigenous-people. Accessed on 30 June 2020

  • Avery OT, Goebel WF (1931) Chemo-immunological studies on conjugated carbohydrate-proteins: v. the immunological specificity of an antigen prepared by combining the capsular polysaccharide of type III Pneumococcus with foreign protein. J Exp Med 54(3):437–447

    Article  CAS  Google Scholar 

  • Bermal N, Szenborn L, Chrobot A, Alberto E, Lommel P, Gatchalian S, Dieussaert I, Lode Schuermanet L (2009) The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/HiB and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J 28(4 Suppl):S89–S96

    Article  Google Scholar 

  • Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA, PCV13 Infant Study Group (2010) Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 125(5):866–875

    Article  Google Scholar 

  • Conklin L, Deloria-Knoll M, Loo J, Fleming-Dutra K, Park D, Johnson TS, Kirk J, Goldblatt D, O’Brien KL, Whitney CG (2011) Landscape analysis of pneumococcal conjugate vaccine dosing schedules: a systematic review; sub report on the 3-dose schedules. A Project of the AVI Technical Assistance Consortium (AVI-TAC) https://www.who.int/immunization/sage/3_Conklin_L_PCV_Dosing_Landscape_Report_Oct_17_2011_FINAL_nov11.pdf. Accessed on 30 June 2020

  • Dagan R, Klugman KP (2008) Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 8(12):785–795

    Article  Google Scholar 

  • Dagan R, Givon-Lavi N, Porat N, Greenberg D (2012) The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. Vaccine 30(34):5132–5140

    Article  Google Scholar 

  • Davies JAV (1937) The response of infants to inoculation with type i pneumococcus carbohydrate. J Immunol 33(1):1–7

    Google Scholar 

  • Desmet S, Verhaegen J, Van Ranst M, Peetermans W, Lagrou K (2018) Switch in a childhood pneumococcal vaccination program from PCV13 to PCV10: a defendable approach? Lancet Infect Dis 18(8):830–831

    Article  Google Scholar 

  • Dinleyici EC, Yargic ZA (2009) Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Expert Rev Vaccines 8(8):977–986

    Article  CAS  Google Scholar 

  • Dochez AR, Avery OT (1917) The elaboration of specific soluble substance by Pneumococcus during growth. J Exp Med 26(4):477–493

    Article  CAS  Google Scholar 

  • EC (2002) European Commission 2002/253/EC. Commission Decision of 19 March 2002 laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament. Official Journal of the European Communities L86/44. https://op.europa.eu/s/n8JV. Accessed on 30 June 2020

  • ECDC (2020) European Centre for Disease Prevention and Control. Disease data for pneumococcal disease from ECDC Surveillance Atlas. https://www.ecdc.europa.eu/en/pneumococcal-disease/surveillance-and-disease-data/atlas. Accessed on 30 June 2020

  • Gajewska M, Goryński P, Paradowska-Stankiewicz I, Lewtak K, Piotrowicz M, Urban E et al (2020) Monitoring of community-acquired pneumonia hospitalisations before the introduction of pneumococcal conjugate vaccine into Polish National Immunization Program (2009–2016): a nationwide retrospective database analysis. Vaccine 38(2):194–201

    Article  Google Scholar 

  • Givon-Lavi N, Greenberg D, Dagan R (2010) Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial. Pediatr Infect Dis J 29(8):756–762

    Article  Google Scholar 

  • Górska-Kot A, Greenberg D, Gastoł K, Zieliński A, Givon-Lavi N (2019) Characterization of acute otitis media otopathogens before the introduction of the pneumococcal conjugated vaccine into the National Immunization Program in Poland. Int J Pediatr Otorhinolaryngol 127:109666

    Article  Google Scholar 

  • Heidelberger M, Avery OT (1923) The soluble specific substance of pneumococcus. J Exp Med 38(1):73–79

    Article  CAS  Google Scholar 

  • Htar MTT, Christopoulou D, Schmitt HJ (2015) Pneumococcal serotype evolution in Western Europe. BMC Infect Dis 15:419

    Article  Google Scholar 

  • Isaacman DJ, McIntosh ED, Reinert RR (2009) Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 14(3):e197–e209

    Article  Google Scholar 

  • Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert RR, Jodar L (2017) Streptococcus pneumoniae serotype 19a: worldwide epidemiology. Expert Rev Vaccines 16(10):1007–1027

    Article  CAS  Google Scholar 

  • IVAC (2017) International Vaccine Access Center. U.S. Centers for Disease Control and Prevention, University College London, Agence de Médecine Préventive, World Health Organization HQ, Pan-American Health Organization: Pneumococcal conjugate vaccine review of impact evidence (PRIME): summary of findings from systematic review. https://www.who.int/immunization/sage/meetings/2017/october/3_FULL_PRIME_REPORT_2017Sep26.pdf. Accessed on 30 June 2020

  • IVAC (2020) International Vaccine Access Center: a report on current global access to new childhood vaccines. VIEW-hub Report: Global Vaccine Introduction and Implementation. https://view-hub.org/sites/default/files/2020-05/VIEW-hub_Report_Mar2020.pdf. Accessed on 30 June 2020

  • Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P (2018) Effectiveness of 7- and 13-valent pneumococcal conjugate vaccines in a schedule without a booster dose: a 10-year observational study. Clin Infect Dis 67(3):367–374

    Article  CAS  Google Scholar 

  • Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Hance LF, Reithinger R, Muenz LR, O'Brien KL (2010) Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 7(10):e1000348

    Article  Google Scholar 

  • Kieninger DM, Kueper K, Steul K, Juergens C, Ahlers N, Baker S, Jansen KU, Devlin C, Gruber WC, Emini EA, Scott DA, 006 study group (2010) Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 28(25):4192–4203

    Article  CAS  Google Scholar 

  • Lister FS (1916) An experimental study of prophylactic inoculation against pneumococcal infection in the rabbit and in man. Publ South Afr Inst Med Res 8:231–287

    Google Scholar 

  • Morais V, Texeira E, Suarez N (2019) Next-generation whole-cell pneumococcal vaccine. Vaccines (Basel) 7(4):151

    Article  CAS  Google Scholar 

  • NIPH-NIH (2019) National Institute of Public Health – National Institute of Hygiene, Department of Epidemiology and Surveillance of Infectious Diseases; Chief Sanitary Inspectorate – Department of Epidemic Prevention and Border Sanitary Protection: Infectious diseases and poisonings in Poland in 2018. http://wwwold.pzh.gov.pl/oldpage/epimeld/2018/Ch_2018.pdf. Accessed on 30 June 2020

  • NRCBM (2019) National Reference Centre for Bacterial Meningitis: Invasive pneumococcal disease in Poland in 2018. http://koroun.nil.gov.pl/wp-content/uploads/2019/07/Inwazyjna-choroba-pneumokokowa-IChP-w-Polsce-w-2018-roku.pdf. Accessed on 30 June 2020

  • NRCBM (2020) National Reference Centre for Bacterial Meningitis: Invasive pneumococcal disease in Poland in 2019. http://koroun.nil.gov.pl/wp-content/uploads/2020/06/Inwazyjna-choroba-pneumokokowa-IChP-w-Polsce-w-2019-roku.pdf. Accessed on 30 June 2020

  • O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T, Hib and Pneumococcal Global Burden of Disease Study Team (2009) Burden of disease caused by streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374(9693):893–902

    Article  Google Scholar 

  • Patrzałek M, Goryński P, Albrecht P (2012) Indirect population impact of universal PCV7 vaccination of children in a 2 + 1 schedule on the incidence of pneumonia morbidity in Kielce, Poland. Eur J Clin Microbiol Infect Dis 31(11):3023–3028

    Article  Google Scholar 

  • Patrzałek M, Kotowska M, Goryński P, Albrecht P (2016) Indirect effects of a 7-year PCV7/pcv13 mass vaccination program in children on the incidence of pneumonia among adults: a comparative study based on two Polish cities. Curr Med Res Opin 32(3):397–403

    Article  Google Scholar 

  • Rinta-Kokko H, Palmu AA, Auranen K, Nuorti JP, Toropainen M, Siira L, Virtanen MJ, Nohynek H, Jokinen J (2018) Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. Vaccine 36(15):1934–1940

    Article  Google Scholar 

  • Scott P, Rutjes AW, Bermetz L, Robert N, Scott S, Lourenço T, Egger M, Low N (2011) Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Vaccine 29(52):9711–9721

    Article  Google Scholar 

  • Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP (2011) Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. mBio 2(1):e00309–e00310

    Article  Google Scholar 

  • Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR (1977) Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 238(24):2613–2616

    Article  CAS  Google Scholar 

  • Stacey HL, Rosen J, Peterson JT, Williams-Diaz A, Vanita G, Sterling TM, Acosta CJ, Nolan KM, Li J, Pedley A, Benner P, Abeygunawardana C, Kosinski M, Smith WJ, Pujar H, Musey LK (2019) Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccin Immunother 15(3):530–539

    Article  Google Scholar 

  • Stein KE (1992) Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 165(Suppl 1):S49–S52

    Article  CAS  Google Scholar 

  • Thompson A, Lamberth E, Severs J, Scully I, Tarabar S, Ginis J, Jansen KU, Gruber WC, Scott DA, Watson W (2019) Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 37(42):6201–6207

    Article  CAS  Google Scholar 

  • Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène JP, Lommel P, Dieussaert I, Schuerman L (2009) Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 28(4 Suppl):S66–S76

    Article  Google Scholar 

  • Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Lukšić I, Nair H, McAllister DA, Campbell H, Rudan I, Black R, Knoll MD (2018) Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health 6(7):e744–e757

    Article  Google Scholar 

  • Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L (2012) Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis 12:207

    Article  Google Scholar 

  • Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A, Active Bacterial Core Surveillance of the Emerging Infections Program Network (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348(18):1737–1746

    Article  Google Scholar 

  • WHO (2008) Estimated Hib and pneumococcal deaths for children under 5 years of age. https://www.who.int/immunization/monitoring_surveillance/burden/estimates/Pneumo_hib/en/. Accessed on 30 June 2020

  • WHO (2019a) Pneumococcal conjugate vaccine in infants and children under 5 years of age: WHO position paper – February 2019. Weekly Epidemiologic Record 94(08):85–104

    Google Scholar 

  • WHO (2019b) Recommendations for routine immunization – summary tables, April 2019. https://www.who.int/immunization/policy/immunization_tables/en/. Accessed on 30 June 2020

  • Wright AE, Morgan WP, Colebrook L, Dodgson RW (1914) Observations on prophylactic inoculation against pneumococcus infections, and on the results which have been achieved by it. Lancet 1:87–95

    Article  Google Scholar 

Download references

Conflicts of Interest

The authors declare no conflicts of interest concerning this article.

Ethical Approval

This review article does not contain any studies with human participants or animals performed by any of the authors.

Funding

This article was funded by the Wroclaw Medical University, subsidy No SUB.C290.19.054.

Author information

Authors and Affiliations

  1. Department of Family Medicine, Faculty of Medicine, Wroclaw Medical University, Wrocław, Poland

    Wojciech Malchrzak & Agnieszka Mastalerz-Migas

Authors
  1. Wojciech Malchrzak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Agnieszka Mastalerz-Migas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Agnieszka Mastalerz-Migas .

Editor information

Editors and Affiliations

  1. Opole Medical School, Opole, Poland

    Mieczyslaw Pokorski

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Malchrzak, W., Mastalerz-Migas, A. (2020). Epidemiologic Benefits of Pneumococcal Vaccine Introduction into Preventive Vaccination Programs. In: Pokorski, M. (eds) Medical Research and Innovation. Advances in Experimental Medicine and Biology(), vol 1324. Springer, Cham. https://doi.org/10.1007/5584_2020_589

Download citation

Publish with us

Policies and ethics

Search

Navigation